4-4-difluoro-4-bora-3a-4a-diaza-s-indacene and Urinary-Bladder-Neoplasms

4-4-difluoro-4-bora-3a-4a-diaza-s-indacene has been researched along with Urinary-Bladder-Neoplasms* in 2 studies

Other Studies

2 other study(ies) available for 4-4-difluoro-4-bora-3a-4a-diaza-s-indacene and Urinary-Bladder-Neoplasms

ArticleYear
Synthesis and in vitro evaluation of a PDT active BODIPY-NLS conjugate.
    Bioorganic & medicinal chemistry letters, 2013, Jun-01, Volume: 23, Issue:11

    Two new photosensitizers based on the BODIPY scaffold have been synthesized, of which one bears an NLS peptide, which is linked to the BODIPY's core using the copper catalysed azide-alkyne click reaction. The phototoxicities of these BODIPY based photosensitizers have been determined, as well as their dark toxicities. Although the conjugation of a single NLS peptide to the BODIPY did not lead to any observable nuclear localization, the photosensitizer did exhibit a superior photoxicity. Cellular co-localization experiments revealed a localization of both dyes in the lysosomes, as well as a partial localization within the ER (for the peptide-bearing BODIPY).

    Topics: Boron Compounds; Cell Line, Tumor; Cell Survival; Drug Evaluation, Preclinical; Humans; Microscopy, Fluorescence; Nuclear Localization Signals; Photochemotherapy; Photosensitizing Agents; Urinary Bladder Neoplasms

2013
Paclitaxel-hyaluronan hydrosoluble bioconjugate: mechanism of action in human bladder cancer cell lines.
    Urologic oncology, 2013, Volume: 31, Issue:7

    A previously described hydrosoluble paclitaxel-hyaluronan bioconjugate appears particularly well suited for treatment of superficial bladder cancer because of its in vitro cytotoxic profile against urothelial carcinoma (UC) cell lines and in vivo biocompatibility. The aim of this work was to assess the mechanism of action of the bioconjugate in UC cells.. Expression of CD44 and RHAMM hyaluronan-binding receptors in RT-4 and RT-112/84 UC cell lines, interaction of fluorochrome-labeled bioconjugate with tumor cells, CD44 modulation upon incubation with the compound or free hyaluronan, and caspase activation were assessed by flow cytometry. Cytotoxicity was studied by the MTT assay. Analysis of bioconjugate intracellular localization and effects on β-tubulin organization was carried out by confocal microscopy.. The paclitaxel-hyaluronan bioconjugate bound to UC tumor cells entered intracellular compartments through a saturable and energy-dependent mechanism that involved CD44, as assessed by blocking with specific antibody. Upon internalization, the bioconjugate accumulated into lysosomes where the esteric bond between paclitaxel and the hyaluronan moiety was cleaved, leading to cytoplasmic diffusion of the free drug, caspase activation, and disruption of the β-tubulin microtubular mesh with subsequent cell death.. Conjugation of paclitaxel to hyaluronan results in a new chemical entity, characterized by selective targeting to polymer receptors on plasma membrane and cell entry through receptor-mediated endocytosis, followed by lysosomal accumulation. Ultimately, the active molecule is released, fully preserving the cytotoxic potential and profile of clinically used free paclitaxel.

    Topics: Antineoplastic Agents; Biological Transport; Boron Compounds; Cell Line, Tumor; Cell Survival; Endocytosis; Fluorescent Dyes; Humans; Hyaluronan Receptors; Hyaluronic Acid; Lysosomes; Microscopy, Confocal; Microtubules; Paclitaxel; Protein Binding; Urinary Bladder Neoplasms

2013